{"id":"NCT00395460","sponsor":"Bayer","briefTitle":"Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients","officialTitle":"A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-04","completion":"2007-04","firstPosted":"2006-11-03","resultsPosted":"2011-11-01","lastUpdate":"2015-06-08"},"enrollment":147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Central Nervous System Diseases"],"interventions":[{"type":"DRUG","name":"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","otherNames":[]},{"type":"DRUG","name":"Magnevist","otherNames":[]}],"arms":[{"label":"Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)","type":"EXPERIMENTAL"},{"label":"GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.","primaryOutcome":{"measure":"Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast Magnetic Resonance Imaging (MRI) Scan of Central Nervous System (CNS) Lesions","timeFrame":"Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast)","effectByArm":[{"arm":"Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)","deltaMin":50.41,"sd":38.448},{"arm":"GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)","deltaMin":43.47,"sd":39.178}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":4,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Insomnia","Nausea","Alanine aminotransferase increased","Aspartate aminotransferase increased","Hyponatraemia"]}}